AN OPEN LABEL SINGLE ARM CLINICAL STUDY ON COMBINED THE COMBINED EFFECTIVENESS OF PANCHANIMBAKAMCHURNA VATI AND PATHYADI LEPA IN KITIBA KUSHTA(PSORIASIS)

SDM College of Ayurveda Hassan1 个研究点分布在 1 个国家目标入组 30 人开始时间: 2021年2月22日最近更新: 2021年2月15日

试验速览

阶段: 不适用
状态: 尚未招募
发起方
入组人数: 30
试验地点: 1
主要终点: Improvement in the PASI scale and symptoms of Kitibha Kushta

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study is an open label single arm prospective clinical study to assess the effectiveness of panchanimbakam churna vati and pathyadi lepa in management of kitibha kushta within age group of 18 to 60 for 30 days in 30 patients. The study will be conducted in one center in India. Secondary outcomes will be assessed by Pasi scale after 30 days

研究设计

研究类型: Interventional
分配方式: Not Applicable
盲法: Not Applicable

入排标准

年龄范围: 18.00 Year(s) 至 60.00 Year(s)（—）
性别: All

入选标准

•Patients suffering with Kitibha Kushta <5years of chronicity.
•Patients of either gender, aged between 18-60 years.
•Patient willing to participate in the study and ready to sign informed consent form.

排除标准

•Patients with systemic illness such as impaired cardiac, renal and hepatic functions.
•Metabolic disorders namely diabetes mellitus type 2 and essential hypertension.
•Pregnant women and lactating women.

结局指标

主要结局

Improvement in the PASI scale and symptoms of Kitibha Kushta

时间窗: outcomes will be assessed at baseline, 15 days and 30 days

次要结局

PASI scale(15 days and 30 days)

研究者

发起方

SDM College of Ayurveda Hassan

申办方类型

Private medical college

研究点 (1)

Loading locations...

相似试验

招募中

2 期

Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative ResectionCarcinoma, Hepatocellular

NCT06454578Qilu Hospital of Shandong University30

Unknown

不适用

A Prospective, Open-label, Single-arm Clinical StudyRecurrent Glioblastoma Multiforme

NCT04689087Sun Yat-sen University40

已完成

Unknown

A clinical study to evaluate the safety and efficacy of Nimson coconut jasmine oil with Vitamin E in improving hair growth

CTRI/2023/06/054302Aryanveda Cosmeceuticals30

招募中

1 期

A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic CancerPancreatic Cancer

NCT06758544Guangdong Provincial People's Hospital18

尚未招募

不适用

Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic CholangiocarcinomaIntrahepatic Cholangiocarcinoma

NCT06313554Fudan University63